NEW YORK (GenomeWeb News) — Accelr8 Technology yesterday said fiscal first-quarter revenues were unchanged though net loss decreased 30 percent.
Total receipts for the three months ended Oct. 31 were flat at $86,000.
Accelr8 said net losses declined to $539,000 from $772,000 in the year-ago period.
The company attributed the decline to reduced research expenses for its BACcelr8r bacterial-analysis system, which is being prepared for clinical trials.
The company had maintained since the fall of 2004 that it would begin marketing the test in its fiscal 2006, which ended July 31, but in June President David Howson admitted that was not going to happen.
The company did not specify yesterday when it expects the test to be available for sale.